MEDI 578

Drug Profile

MEDI 578

Alternative Names: Anti-NGF monoclonal antibody (MEDI-578); MEDI-578

Latest Information Update: 09 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Antirheumatics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Musculoskeletal pain

Most Recent Events

  • 30 Jun 2012 Discontinued - Phase-I for Musculoskeletal pain in United Kingdom (IV)
  • 13 Jul 2010 Suspended - Phase-I for Musculoskeletal pain (in osteoarthritis patients) in United Kingdom (IV)
  • 28 Feb 2010 Phase-I clinical trials in Musculoskeletal pain (in osteoarthritis patients) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top